NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » TOP 50 Pharmas  «  1  2  3  4  5  » 
found files: 188
Schering-Plough »14/08/2008 [Company watch]
Schering-Plough Takes Sole Possession of Its China JV

Schering-Plough Corporation bought the 45% of its majority-owned China JV, Shanghai Schering-Plough Pharmaceutical, that it did not already own. Its former partners, Shanghai Pharmaceutical Group and Shanghai Pharmaceutical Industry Corporation, put the 45% stake up for sale in May, saying they wanted to streamline their business into fewer subsidiaries. At the time, the two companies were asking 66.3 million RMB ($9.6 million) for their stake. Schering-Plough did not disclose the final price. Schering-Plough representatives portrayed the acquisition as an expansion of the company’s involvement in China. Established in 1994, the JV manufactures, markets and distributes allergy and skincare products. In China, Schering-Plough is active in the therapeutic areas of allergy/respiratory, cardiovascular, central nervous system, skin care, oncology, infectious diseases, and women's health. The JV, which employs more than 1,000 people in China, posted a net profit of $500,000 in 2007 after two years of losses. It was formed two years after Schering-Plough opened its first offices in China cities, though the company has been selling pharmaceuticals in the China market since the 1980s....   more»


Boehringer Ingellheim »28/08/2008 [Company watch]
Boehringer Ingelheim to sign cooperation with HISOAR in China

Within the the framework of this production alliance Boehringer Ingelheim complements its worldwide chemical production network with strong partners for the manufacturing of chemical intermediates for its active pharmaceutical ingredients (APIs). Taizhou/China and Ingelheim/Germany, 28 August 2008 - Boehringer Ingelheim and Hisoar, a Chinese pharmaceutical production company based in Taizhou, today jointly announced a strategic production alliance in China. Within the the framework of this production alliance Boehringer Ingelheim complements its worldwide chemical production network with strong partners for the manufacturing of chemical intermediates for its active pharmaceutical ingredients (APIs). These chemicals will then be processed further in Boehringer Ingelheim’s plants in Germany, Italy, Spain and the United States. From September 2008 onwards, Boehringer Ingelheim will supply know-how as well as technical support for production to Hisoar. Hisoar in turn will invest into new specific production facilities for Boehringer Ingelheim at its new site in Chuannan. The production for Boehringer Ingelheim in Chuannan is planned to start in early 2009. Mr. Bangpeng Luo, the Chairman of Hisoar commented: We are very pleased to have the opportunity to cooperate with Boehringer Ingelheim, a large multinational pharmaceutical company. This cooperation, both from the technical and the management level, will raise Hisoar’s market positioning and standing and it will create an unusual benefit for Hisoar to enter the international levelof raw material suppliers, and indicates that Hisoar has come a big step forward towards internationalization.” Dr Hans-JĂĽrgen Leuchs, Member of the Board of Managing Directors and responsible for the Corporate Board Division Operations of Boehringer Ingelheim added, “Boehringer Ingelheim is looking forward to a fruitful cooperation with our Chinese partner to have in future more flexibility, short production timelines and an appropriate capacity for the continuously growing demand for Boehringer Ingelheim’s medications across the globe.”...   more»


Roche »29/08/2008 [Company watch]
Roche oral chemotherapeutic Xeloda granted SFDA approval

Shanghai Roche Pharmaceuticals, the China branch of multinational giant Roche, announced on August 26th that it has obtained approval from the SFDA to market its oral chemotherapy drug Xeloda (capecitabine) in China as a first line treatment for late stage gastric cancer. The drug provides an alternative to standard intravenous injection chemotherapies. The product, a 5-FU prodrug, is approved in the United States for treatment of both metastatic colorectal and breast cancers...   more»


Merck & Co »04/09/2008 [Company watch]
Merck Serono and Ablynx Enter into an Agreement to Co-Discover and Co-Develop Nanobodies®

• Merck Serono and Ablynx to equally contribute to discover and develop Nanobodies® against two targets in oncology and immunology and equally share the resulting profits Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that it has entered into an agreement with Ablynx (Euronext Brussels: ABLX), to co-discover and co-develop Nanobodies® against two targets in oncology and immunology. The agreement includes an upfront cash payment to Ablynx of €10 million. Nanobodies® are a new class of therapeutic proteins that contain the unique structural and functional properties of naturally-occurring single domain antibodies. The partners will collaborate to research and develop Nanobody®-based therapeutics against two disease targets exploiting some of the key benefits Nanobodies® have over conventional antibodies and other fragments. Under the terms of the agreement, both companies will equally share all research and development costs. Should Ablynx contribute equally to each program, it will be eligible to receive fifty percent of the resulting profits. In addition, Ablynx will have an option to opt-out partly or fully during the research and development programs, in which case the company would be eligible to receive either a reduced profit share, in the case of a partial opt-out, or milestones and royalties on potential sales, in the case of a full opt- out. Total development and commercial milestones, depending on the point of opt-out by Ablynx, could reach up to €325 million should a product be approved in multiple indications in all major markets. “This collaboration reinforces our commitment to deliver innovative treatments in areas of high unmet medical needs,” said Dr Bernhard Kirschbaum, Executive Vice President Research of Merck Serono. "We believe that Nanobodies® have the potential to provide innovative drugs combining the best features of monoclonal antibodies and small molecules, and we look forward to working with Ablynx." "We are very pleased to enter into this partnership with Merck Serono, a recognized global leader in the treatment of oncology and immunology therapies. This type of risk and reward sharing collaboration underlines Ablynx’s maturing capabilities and collaboration strategy, whereby we can leverage on the resources and expertise of our partners to advance Nanobodies® more quickly into the clinic while retaining an equal share of the value created", commented Dr Edwin Moses, CEO and Chairman of Ablynx....   more»


Pfizer »09/09/2008 [Company watch]
Pfizer and Medivation Enter into Global Agreement to Co-Develop and Market Dimebon for the Treatment of Alzheimer\'s and Huntington\'s Diseases

Pfizer Inc and Medivation, Inc. announced today that they have entered into an agreement to develop and commercialize Dimebon, Medivation\'s investigational drug for treatment of Alzheimer\'s disease and Huntington\'s disease. Dimebon currently is being evaluated in an international, confirmatory Phase III trial in patients with mild-to-moderate Alzheimer\'s disease (www.connectionstudy.com). Under the terms of the agreement, Medivation will receive an up-front cash payment of $225 million. Medivation also is eligible to receive payments of up to $500 million upon the attainment of development and regulatory milestones plus additional undisclosed commercial milestone payments. Medivation and Pfizer will collaborate on the Phase III program in Alzheimer\'s disease, Huntington\'s disease development and regulatory filings in the United States. The companies will share all U.S. development and commercialization expenses along with U.S. profits/losses on a 60 percent/40 percent basis, with Pfizer assuming the larger share of both expenses and profit/losses. In addition, Medivation will co-promote Dimebon to specialty physicians in the U.S. Pfizer will have responsibility for development, regulatory and commercialization outside the U.S. and will pay Medivation tiered royalties on commercial sales outside of the U.S. The agreement is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. J.P. Morgan served as financial advisor, and Cooley Godward Kronish LLP served as legal advisor, to Medivation on this transaction. Alzheimer\'s disease leads to the death of brain cells and the loss of nerve connections in areas of the brain that govern memory, thinking and behavior. Alzheimer\'s disease gradually destroys a person\'s memory and ability to learn, reason, make judgments, communicate and carry-out daily activities. No currently marketed Alzheimer\'s disease drug appears to stop brain cell death and prevent or restore lost nerve connections. Dimebon is an orally-available, small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer\'s disease and Huntington\'s disease, making it a potential treatment for these and other neurodegenerative conditions. Based on preclinical data generated to date, Dimebon appears to improve the function of mitochondria, the energy generators in cells that play a vital role in governing brain cell health, growth and overall function. Dimebon also has been shown to stimulate the outgrowth of nerves from brain cells, or neurites, a process that is believed to play an important role in restoring or generating new brain cell connections. \"With more than 18 million people worldwide suffering from the debilitating and ultimately fatal effects of Alzheimer\'s disease, Pfizer has made this devastating illness one of our highest priorities,\" said Dr. Martin Mackay, president, Pfizer Global Research and Development. \"We are working to develop new medicines that improve memory and halt or significantly slow the disease\'s progression. We look forward to collaborating with Medivation to bring Dimebon to patients as rapidly as possible.\" \"After a rigorous process that garnered substantial interest, we believe that Pfizer is the ideal partner, sharing our vision for Dimebon and capable of maximizing its potential globally,\" said Dr. David Hung, president and chief executive officer of Medivation. \"As one of the leaders in Alzheimer\'s disease, Pfizer is an optimal partner because of its extensive experience developing new medicines; its marketing and commercialization track record; and, its significant global capability to effectively reach primary care physicians, who today prescribe the vast majority of Alzheimer\'s disease medications in the U.S.\" About Dimebon\'s Clinical Program Results from the first pivotal trial of Dimebon in Alzheimer\'s disease showed that patients treated with Dimebon experienced statistically significant improvements compared to placebo in key aspects of the disease -- memory and thinking, activities of daily living, behavior and overall function. Dimebon\'s benefit over placebo continued to increase throughout the 12-month treatment period. At the end of 12 months, Dimebon-treated patients were on average functioning as well or better than they had been at the start of the study on each of 5 clinical endpoints. These results were published in the July 19, 2008 issue of The Lancet, and are noteworthy as untreated Alzheimer\'s patients progressively deteriorate over time in these areas. On July 7, 2008, Medivation announced positive safety and efficacy results from its Phase 2 trial of Dimebon in Huntington\'s disease, which was conducted in collaboration with the Huntington Study Group. Dimebon appeared to be well tolerated and showed statistically significant benefit versus placebo in cognition as measured by the Mini-Mental State Examination, a secondary endpoint in the study....   more»


Sanofi-Aventis »15/10/2008 [Company watch]
Sanofi cuts ribbon on Shenzhen vaccine plant

Sanofi-Aventis held an opening ceremony October 12 for the completed phase I construction of its vaccine plant in Shenzhen. The new plant is expected to be running at full steam by 2012 with an output capacity of 2.5 million doses of seasonal influenza vaccine per year. Sanofi Pasteur, the vaccines division of Sanofi-Aventis, began construction of the plant, a total scheduled investment of RMB 670 million, in the beginning of 2008. According to Wayne Pisano, president and CEO of Sanofi Pasteur, the rate of vaccination for influenza is only 2%, much lower than the 20% and 40% rate in Europe and North America....   more»


Eli Lilly & Co »16/10/2008 [Company watch]
Eli Lilly & Co. Opens China R&D Headquarters in Shanghai

Eli Lilly & Co. announced that it set up a Chinese R&D headquarters in Shanghai. The Shanghai headquarters will organize a team that is responsible for R&D management and venture capital investments to seek, promote and manage the company's cooperation with Chinese companies and R&D institutes. In details, it will manage those outsourcing and risk-sharing R&D projects, transfers of alternative medicines and technologies, and VC investments in medical sector of the Greater China Region. The headquarters is located in the Shanghai Zhangjiang Hi-tech Park and nears bases of many of the company's partners. The new headquarters provides an important point of convergence for Lily's innovation network. Eli Lilly Mulls Acquisitions Eli Lilly & Co. said that there may be acquisition opportunities for the company in the next year or two. The company will look at expanding its presence in biotechnology. Chief Executive John Lechleiter, said: “Right now the biotech companies are probably going to struggle the most in this environment.” The chief said that: There would probably be opportunities for his company to pursue partnerships, acquisitions, licensing or other types of deals in the next year or two. “I think you can expect to see us be opportunistic,” he added. The company is also interested in expanding in areas such as oncology. “For the kinds of the things we'll need to do and for the kinds of acquisition we'll need to make, we believe between our cash position and our debt position we'll be able to execute on those,” he added. The Shanghai headquarters will organize a team that is responsible for R&D management and venture capital investments to seek, promote and manage the company's cooperation with Chinese companies and R&D institutes. In details, it will manage those outsourcing and risk-sharing R&D projects, transfers of alternative medicines and technologies, and VC investments in medical sector of the Greater China Region. The headquarters is located in the Shanghai Zhangjiang Hi-tech Park and nears bases of many of the company's partners. The new headquarters provides an important point of convergence for Lily's innovation network, said Robert Armstrong, Lily's vice president of global external R&D. Establishment of the headquarters indicates that the company intends to make in-depth investment in China and has growing confidence over Chinese companies' creativity, efficiency and capacity on biomedical R&D, said Bill Chin, vice president of Lily's discovery research and clinical investigation....   more»


Sanofi-Aventis »21/10/2008
Sanofi-Aventis expands its R&D presence in China

Sanofi-aventis announced today the strengthening of its R&D presence in China, with the expansion of its R&D facility in Shanghai, the new establishment of a state-of-the-art Biometrics Center in Beijing, and the signature of a partnership agreement with the Shanghai Institutes for Biological Sciences (SIBS) for the discovery of breakthrough drugs for neurological diseases, diabetes, and cancer....   more»


Roche »07/11/2008 [Company watch]
Roche Intent on Discovering Innovative Medicines in China

Roche has broken ground on an expansion of its facilities at its site in Shanghai’s Zhangjiang Hi-Tech Park, an ambitious expansion that seeks to provide the backbone for the next ten years of the company’s China growth....   more»


Novo Nordisk »07/11/2008 [Company watch]
Novo Nordisk reveals major Chinese investment

Novo Nordisk has revealed it is investing close to $400 million (ÂŁ254 million) in a production facility in China....   more»


Bayer »14/11/2008 [Company watch]
Bayer to develop hemophilia treatment centres in China

German-based pharmaceutical company, Bayer Schering , announced a $1.9 million pledge to develop Hemophilia Treatment Centers (HTCs) throughout China....   more»


GlaxoSmithKline »13/11/2008 [Company watch]
GSK keen on China for R&D

China plays a key role in the global strategy and development of GlaxoSmithKline....   more»


Roche »17/11/2008 [Company watch]
European drug giant Roche is expanding its Shanghai facility in China

European drug giant Roche is expanding its Shanghai facility in China to bolster business in the world’s fastest growing economy and to develop innovative drugs in China....   more»


Eli Lilly & Co »21/11/2008 [Company watch]
Hutchison China, Eli Lilly expand drug deal

(Reuters) - Hutchison China Meditech Ltd a traditional Chinese medicine-sourced pharmaceuticals maker, said on Friday it has expanded its drug discovery and development partnership with Eli Lilly and Co (focused on an additional target in oncology....   more»


GlaxoSmithKline »24/11/2008 [Company watch]
GSK in a JV to develop flu vaccines, targets China

Pharmaceutical major, GlaxoSmithKline (GSK) has signed a cooperation agreement with Chinese company, Shenzhen Neptunus Interlong Bio-Technique (NIBT) to form a Joint Venture (JV) between the companies....   more»


Pfizer »20/11/2008 [Company watch]
Stiff legal battle over Viagra continues, Pfizer wins latest round

Pfizer\'s drawn out battle with Guangzhou Welman Pharmaceutical continues, this time with the courts ruling in favor of the multinational drug giant in a counter suit filed by Welman....   more»


GlaxoSmithKline »01/12/2008 [Company watch]
GSK and Neptunus sign cooperation agreement to form joint venture

GlaxoSmithKline (GSK) announced that it has signed an exclusive Cooperation Agreement with Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. (NIBT) as a preliminary step in forming a Joint Venture (JV) between the two companies....   more»


Eli Lilly & Co »29/11/2008 [Company watch]
Lilly Adds Oncology Target to Chi-Med Collaboration

Eli Lilly has expanded its drug discovery and development partnership with Hutchison China Meditech Ltd, adding another oncology target to the agenda. When the two companies set up their partnership last year, the initial areas of concentration were specified targets in oncology and inflammation....   more»


Schering-Plough »15/12/2008 [Company watch]
Huya Bioscience today announced an agreement with Schering-Plough

HUYA Bioscience International, a leader in US/China pharmaceutical co-development, today announced an agreement with Schering-Plough Corporation\'s subsidiary, N.V. Organon....   more»


Merck & Co »14/12/2008 [Company watch]
Merck to move into biotech market

Merck has announced plans to move into biotechnology medicine and break into the generic biotech market....   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.